OSAKA -- Japanese pharmaceutical company Shionogi has begun a Phase 1 trial of an antiviral pill for COVID-19 patients with light symptoms, joining peers worldwide in seeking a therapy to treat infected people at home.
Shionogi's pill would require just one oral dose daily for several days, while similar drugs in development in Japan would need to be taken at least twice daily, the company said Monday.
